Supplementary Figure S10 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
journal contribution
posted on 2024-12-02, 08:41 authored by Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. SteinThis dataset provides important insights into botensilimab's effects on the myeloid compartment of the immune system. The increase in CD11c+ HLA-DR+ myeloid cells, which likely represent antigen-presenting cells, suggests that botensilimab may enhance antigen presentation and T cell activation. The lack of effect on CD16- myeloid cells indicates a selective impact on specific myeloid subsets. These findings contribute to understanding botensilimab's unique mechanism of action, suggesting it may enhance anti-tumor immunity not only through effects on T cells but also by modulating myeloid cell populations.
